Monday, 11 May 2015 10:09

Biosimilar reimbursement pathways: CMS guidance and outstanding issues

Written by 
Rate this item
(1 Vote)
The Centers for Medicare & Medicaid Services (CMS) recently issued three guidances regarding reimbursement for biosimilars under Medicare Parts B and D, as well as under Medicaid. These guidances address questions that have arisen regarding reimbursement policies that CMS will implement for biosimilars.
Read 126295 times

More in this category: A new class of drugs is here »


Global Database Search

 knowyoursubtype iconb   facebook2 twitter2 youtube1




The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.

Copyright © 2017 Lymphoma Coalition. All rights reserved.